Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward

Open access
Martinez, Fernando J., Agusti, Alvar, Celli, Bartolome R., Han, MeiLan K., Allinson, James P., Bhatt, Surya P., Calverley, Peter, Chotirmall, Sanjay H., Chowdhury, Badrul, Darken, Patrick, Da Silva, Carla A., Donaldson, Gavin, Dorinsky, Paul, Dransfield, Mark, Faner, Rosa, Halpin, David M., Jones, Paul, Krishnan, Jerry A., Locantore, Nicholas, Martinez, Fernando D., Mullerova, Hana, Price, David, Rabe, Klaus F., Reisner, Colin, Singh, Dave, Vestbo, Jørgen, Vogelmeier, Claus F., Wise, Robert A., Tal-Singer, Ruth, Wedzicha, Jadwiga A. · 2022 · American Journal of Respiratory and Critical Care Medicine

Abstract

Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene–environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: “young” individuals with COPD and those with pre-COPD. Given that lungs grow to about 20 years of age and begin to age at approximately 50 years, we consider “young” patients with COPD those patients in the age range of 20–50 years. Pre-COPD relates to individuals of any age who have respiratory symptoms with or without structural and/or functional abnormalities, in the absence of airflow limitation, and who may develop persistent airflow limitation over time. We exclude from the current discussion infants and adolescents because of their unique physiological context and COPD in older adults given their representation in prior randomized controlled trials (RCTs). We highlight the need of RCTs focused on COPD in young patients or pre-COPD to reduce disease progression, providing innovative approaches to identifying and engaging potential study subjects. We detail approaches to RCT design, including potential outcomes such as lung function, patient-reported outcomes, exacerbations, lung imaging, mortality, and composite endpoints. We critically review study design components such as statistical powering and analysis, duration of study treatment, and formats to trial structure, including platform, basket, and umbrella trials. We provide a call to action for treatment RCTs in 1) young adults with COPD and 2) those with pre-COPD at any age.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202107-1663so

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Martinez, F. J., Agusti, A., Celli, B. R., Han, M. K., Allinson, J. P., Bhatt, S. P., Calverley, P., Chotirmall, S. H., Chowdhury, B., Darken, P., Da Silva, C. A., Donaldson, G., Dorinsky, P., Dransfield, M., Faner, R., Halpin, D. M., Jones, P., Krishnan, J. A., Locantore, N., Martinez, F. D., Mullerova, H., Price, D., Rabe, K. F., Reisner, C., Singh, D., Vestbo, J., Vogelmeier, C. F., Wise, R. A., Tal-Singer, R., & Wedzicha, J. A.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2022-02-01
Volume
205
Issue
3
Pages
275-287
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W3206293932
Cited by
163
References
8
FWCI
14.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.